Infliximab induction and maintenance therapy for ulcerative colitis: the ACT 2 trialWJ Sandborn, J F Colombel, Walter Reinisch et al.|Zeitschrift für Gastroenterologie|2005Cited by 51
OC-057 A PH3 Randomised, Multicenter, Double-Blind, Placebo (PBO)-Controlled Study of Ustekinumab (UST) Maintenance Therapy in Moderate–Severe Crohn’s Disease (CD) PTS: Results from IM-UNITIWJ Sandborn, Bruce E. Sands, S. B. Hanauer et al.|Unknown|2016Cited by 11
Efficacy and Safety of Ustekinumab as Maintenance Therapy in Ulcerative Colitis: Week 44 Results from UNIFIWJ Sandborn, Colleen Marano, BE Sands et al.|Zeitschrift für Gastroenterologie|2019Cited by 7
OC-007 A Multicenter, Double-Blind, Placebo (PBO)-Controlled Ph3 Study of Ustekinumab (UST), AHuman MAB to IL-12/23P40, IN PTS with Moderately-Severely Active Crohn’s Disease (CD) Who are Naïve or not Refractory to anti-TNFΑ: UNITI-2B. Feagan, WJ Sandborn, Christopher Gasink et al.|Unknown|2016Cited by 6
Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double-blind, placebo-controlled phase2b study of Ustekinumab in patients with moderately to severely active Crohnʼs diseaseBE Sands, B. Feagan, Christopher Gasink et al.|Inflammatory Bowel Diseases|2011Cited by 5